Gut-Vagal Pathway Research Priorities

1 Background and Rationale

Wirth and Scheibenbogen (Wirth and Scheibenbogen 2025) proposed that gut dysbiosis impairs enterochromaffin cell serotonin synthesis, reducing vagal afferent signalling and contributing to the autonomic dysfunction characteristic of ME/CFS@. This model is supported by documented butyrate-producer deficiency in ME/CFS microbiome studies (Guo et al. 2023) and established mechanisms linking butyrate, enterochromaffin serotonin, and vagal activation (Barton et al. 2025) The following research priorities would test this model and identify a “gut-vagal” ME/CFS subtype for targeted intervention.

2 Priority Study 1: Cross-Sectional Gut-Vagal Phenotyping

2.1 Hypothesis

ME/CFS patients with prominent GI symptoms have lower resting HRV, lower butyrate-producing bacterial abundance, and lower platelet serotonin than ME/CFS patients without GI involvement and healthy controls. These markers cluster to identify a distinct gut-vagal subtype.

2.2 Design

  • Type: Cross-sectional case-control, n=100–200 (ME/CFS with GI symptoms, ME/CFS without GI symptoms, healthy controls)
  • Primary measures: 5-minute resting HRV; stool microbiome (focus on F. prausnitzii and butyrate-producer abundance); platelet serotonin; 24-hour urinary 5-HIAA; fecal short-chain fatty acids
  • Secondary measures: Kynurenine/tryptophan ratio (IDO activity marker; operationalises the EBV–IDO2–gut-vagal chain in Speculation EBV Reactivation Impairs Gut-Vagal Signalling via IDO2: patients with EBV reactivation predicted to show higher k/t ratios, lower platelet serotonin, and worse HRV); EBV serology (IgG titres, EBNA, VCA antibodies; planned subgroup analysis of k/t ratio and HRV stratified by EBV reactivation status); serum tryptase and 24-hour urinary methylhistamine (MCAS markers; tests the bidirectional mast cell–enterochromaffin amplification mechanism); serum chromogranin A; GI symptom severity; fatigue severity; orthostatic tolerance
  • Analysis: Cluster analysis to identify whether gut-vagal markers co-vary; correlation of butyrate-producer abundance with HRV and fatigue; subgroup analysis of EBV-seropositive vs. EBV-seronegative patients on k/t ratio, platelet serotonin, and HRV; correlation of tryptase and methylhistamine with HRV and fatigue scores
  • Timeline: 6–12 months

2.3 Expected Outcomes

If gut-vagal markers cluster in a subgroup, this establishes the foundation for targeted intervention trials. HRV and stool microbiome testing are both accessible and could serve as simple screening tools for this subtype.

3 Priority Study 2: Butyrate Supplementation RCT

3.1 Hypothesis

Tributyrin supplementation at 2 g three times daily (the upper end of the 1–2 g clinical range; see Section Probiotics and Gut Health in Chapter Supplements and Nutraceuticals) improves HRV and reduces fatigue in ME/CFS patients with documented butyrate-producer deficiency, compared to placebo.

3.2 Design

  • Type: Randomised, double-blind, placebo-controlled; n=60 (30 tributyrin, 30 placebo)
  • Duration: 12 weeks
  • Stratification: Randomise within strata defined by baseline butyrate-producer abundance (low vs. moderate) to test whether response is greatest in most-deficient patients
  • Primary outcome: Change in resting HRV at 12 weeks
  • Secondary outcomes: Fatigue severity (SF-36 vitality, FACIT-Fatigue), GI symptom score, stool microbiome, platelet serotonin, orthostatic tolerance
  • Timeline: 12–18 months

3.3 Expected Outcomes

A positive result would provide the first RCT evidence for a microbiome-vagal mechanism in ME/CFS and support butyrate supplementation as a disease-modifying intervention in the gut-vagal subtype. A null result in the full population but positive result in the low-butyrate stratum would support biomarker-guided treatment selection.

4 Priority Study 3: HRV-Guided Phenotype Reanalysis

4.1 Rationale

Multiple existing ME/CFS cohorts include HRV data. A secondary analysis stratifying by baseline HRV could test whether low-HRV patients have more GI symptoms and different microbiome profiles than high-HRV patients—testing the gut-vagal subtype hypothesis at low cost before embarking on prospective studies.

4.2 Design

  • Type: Secondary analysis of existing datasets
  • Key datasets: Any ME/CFS cohort with HRV, GI symptom, and microbiome data (e.g., Giloteaux et al. Cornell cohort (Giloteaux et al. 2016))
  • Analysis: Correlate HRV with GI symptom severity, butyrate-producer abundance, and fatigue scores; test whether HRV clusters identify a distinct subgroup
  • Timeline: 3–6 months
  • Cost: Low (secondary analysis, no new data collection)

References

Barton, Warrick, Gustav Colldén, Julia Brooks, Sarah Lowrance, and Carolyn Woods. 2025. “Interaction of the Vagus Nerve and Serotonin in the Gut–Brain Axis.” International Journal of Molecular Sciences 26 (3): 1160. https://doi.org/10.3390/ijms26031160.
Giloteaux, Ludovic, Julia K. Goodrich, William A. Walters, Susan M. Levine, Ruth E. Ley, and Maureen R. Hanson. 2016. “Reduced Diversity and Altered Composition of the Gut Microbiome in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Microbiome 4: 30. https://doi.org/10.1186/s40168-016-0171-4.
Guo, Cheng, Xiaoyu Che, Thomas Briese, Amit Alber, Taylor Alpert, Lia Zhang, Yilin Yu, et al. 2023. “Deficient Butyrate-Producing Capacity in the Gut Microbiome Is Associated with Bacterial Network Disturbances and Fatigue Symptoms in ME/CFS.” Cell Host and Microbe 31 (2): 288–304. https://doi.org/10.1016/j.chom.2023.01.004.
Wirth, Klaus J., and Carmen Scheibenbogen. 2025. “Imbalance of Excitatory and Inhibitory Neurotransmitter Pathways in ME/CFS and Long COVID.” Preprints.org (preprint, not peer-reviewed). https://www.preprints.org/frontend/manuscript/025f093892ed0dc2aef00d95d0f2fb85/download_pub.